AU2019340845B2 - Method for producing an antitumoral arenavirus as well as arenavirus mutants - Google Patents
Method for producing an antitumoral arenavirus as well as arenavirus mutantsInfo
- Publication number
- AU2019340845B2 AU2019340845B2 AU2019340845A AU2019340845A AU2019340845B2 AU 2019340845 B2 AU2019340845 B2 AU 2019340845B2 AU 2019340845 A AU2019340845 A AU 2019340845A AU 2019340845 A AU2019340845 A AU 2019340845A AU 2019340845 B2 AU2019340845 B2 AU 2019340845B2
- Authority
- AU
- Australia
- Prior art keywords
- lcmv
- seq
- pct
- rule
- substitute sheet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
- C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102018215551.8 | 2018-09-12 | ||
| DE102018215551.8A DE102018215551A1 (de) | 2018-09-12 | 2018-09-12 | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| PCT/EP2019/074307 WO2020053324A1 (en) | 2018-09-12 | 2019-09-12 | Method for producing an antitumoral arenavirus as well as arenavirus mutants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019340845A1 AU2019340845A1 (en) | 2021-05-06 |
| AU2019340845B2 true AU2019340845B2 (en) | 2026-01-29 |
Family
ID=68138008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019340845A Active AU2019340845B2 (en) | 2018-09-12 | 2019-09-12 | Method for producing an antitumoral arenavirus as well as arenavirus mutants |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12129281B2 (enExample) |
| EP (2) | EP4019533A1 (enExample) |
| JP (1) | JP7583448B2 (enExample) |
| KR (1) | KR20210057782A (enExample) |
| CN (2) | CN120158432A (enExample) |
| AU (1) | AU2019340845B2 (enExample) |
| BR (1) | BR112021004451A2 (enExample) |
| CA (1) | CA3111305A1 (enExample) |
| CL (1) | CL2021000592A1 (enExample) |
| DE (1) | DE102018215551A1 (enExample) |
| DK (1) | DK3694868T3 (enExample) |
| ES (1) | ES2908854T3 (enExample) |
| IL (1) | IL281299B2 (enExample) |
| MX (1) | MX2021002937A (enExample) |
| PH (1) | PH12021550424A1 (enExample) |
| SG (1) | SG11202101970UA (enExample) |
| WO (1) | WO2020053324A1 (enExample) |
| ZA (1) | ZA202101833B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024508823A (ja) * | 2021-02-26 | 2024-02-28 | アバロス セラピューティクス ゲーエムベーハー | 治療目的のための新規のウイルス粒子 |
| WO2025046106A1 (en) * | 2023-08-31 | 2025-03-06 | Abalos Therapeutics Gmbh | Virus particles with improved entry into tumor cells |
| CN117867030A (zh) * | 2024-01-15 | 2024-04-12 | 苏州健雄职业技术学院 | 小鼠肺癌细胞系cmt167荧光素酶稳转细胞株的构建与应用 |
| CN121022940B (zh) * | 2025-10-30 | 2026-04-07 | 山东第一医科大学(山东省医学科学院) | 一种抑制塔姆德病毒感染的方法及tcp1抑制剂的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124308A1 (en) * | 2004-07-16 | 2008-05-29 | Laer M Dorothee | Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins |
| JP2012503489A (ja) * | 2008-09-24 | 2012-02-09 | メディミューン，エルエルシー | ウイルスの精製方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2604695T (lt) | 2007-12-27 | 2022-12-12 | Universität Zürich | Replikacijos defektų turintys arenaviruso vektoriai |
| RU2585216C2 (ru) | 2009-03-23 | 2016-05-27 | Институт Пастор | Мутантные полипептиды суаа и производные полипептидов, подходящие для доставки иммуногенных молекул в клетку |
| WO2012093340A2 (en) * | 2011-01-07 | 2012-07-12 | Bioscience Slovakia | Viral diagnostics |
| US20150307559A1 (en) | 2012-12-12 | 2015-10-29 | Children's Hospital Of Eastern Ontario Research Intitute Inc. | Compositions and methods for the treatment of brain cancers |
| DE102015207036A1 (de) * | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| EP3173092B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| WO2018083220A2 (en) * | 2016-11-04 | 2018-05-11 | Hookipa Biotech Ag | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
-
2018
- 2018-09-12 DE DE102018215551.8A patent/DE102018215551A1/de not_active Withdrawn
-
2019
- 2019-09-12 WO PCT/EP2019/074307 patent/WO2020053324A1/en not_active Ceased
- 2019-09-12 AU AU2019340845A patent/AU2019340845B2/en active Active
- 2019-09-12 ES ES19782905T patent/ES2908854T3/es active Active
- 2019-09-12 KR KR1020217010631A patent/KR20210057782A/ko active Pending
- 2019-09-12 EP EP21205198.1A patent/EP4019533A1/en active Pending
- 2019-09-12 IL IL281299A patent/IL281299B2/en unknown
- 2019-09-12 JP JP2021514594A patent/JP7583448B2/ja active Active
- 2019-09-12 MX MX2021002937A patent/MX2021002937A/es unknown
- 2019-09-12 US US17/275,967 patent/US12129281B2/en active Active
- 2019-09-12 CN CN202510196120.1A patent/CN120158432A/zh active Pending
- 2019-09-12 SG SG11202101970UA patent/SG11202101970UA/en unknown
- 2019-09-12 CA CA3111305A patent/CA3111305A1/en active Pending
- 2019-09-12 BR BR112021004451-5A patent/BR112021004451A2/pt unknown
- 2019-09-12 CN CN201980074560.2A patent/CN112996802B/zh active Active
- 2019-09-12 DK DK19782905.4T patent/DK3694868T3/da active
- 2019-09-12 EP EP19782905.4A patent/EP3694868B1/en active Active
-
2021
- 2021-03-01 PH PH12021550424A patent/PH12021550424A1/en unknown
- 2021-03-10 CL CL2021000592A patent/CL2021000592A1/es unknown
- 2021-03-18 ZA ZA2021/01833A patent/ZA202101833B/en unknown
-
2024
- 2024-10-25 US US18/927,732 patent/US20250122244A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124308A1 (en) * | 2004-07-16 | 2008-05-29 | Laer M Dorothee | Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins |
| JP2012503489A (ja) * | 2008-09-24 | 2012-02-09 | メディミューン，エルエルシー | ウイルスの精製方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN120158432A (zh) | 2025-06-17 |
| US12129281B2 (en) | 2024-10-29 |
| IL281299A (en) | 2021-04-29 |
| ZA202101833B (en) | 2022-10-26 |
| IL281299B2 (en) | 2025-07-01 |
| CN112996802B (zh) | 2025-03-11 |
| BR112021004451A2 (pt) | 2021-06-01 |
| US20250122244A1 (en) | 2025-04-17 |
| ES2908854T3 (es) | 2022-05-04 |
| CL2021000592A1 (es) | 2021-09-10 |
| MX2021002937A (es) | 2021-07-16 |
| EP3694868A1 (en) | 2020-08-19 |
| NZ774584A (en) | 2024-09-27 |
| CN112996802A (zh) | 2021-06-18 |
| SG11202101970UA (en) | 2021-03-30 |
| DK3694868T3 (da) | 2022-02-07 |
| KR20210057782A (ko) | 2021-05-21 |
| US20220033445A1 (en) | 2022-02-03 |
| CA3111305A1 (en) | 2020-03-19 |
| EP3694868B1 (en) | 2021-11-03 |
| AU2019340845A1 (en) | 2021-05-06 |
| IL281299B1 (en) | 2025-03-01 |
| WO2020053324A1 (en) | 2020-03-19 |
| EP4019533A1 (en) | 2022-06-29 |
| DE102018215551A1 (de) | 2020-03-12 |
| JP2022500054A (ja) | 2022-01-04 |
| JP7583448B2 (ja) | 2024-11-14 |
| PH12021550424A1 (en) | 2021-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250122244A1 (en) | Method for producing an antitumoral arenavirus as well as arenavirus mutants | |
| JP6959258B2 (ja) | 改変された腫瘍溶解性ウイルス | |
| JP6890831B2 (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| AU2021261945B2 (en) | Compositions and methods for generating an immune response to a tumor associated antigen | |
| EP3562946B1 (en) | Oncolytic viruses and therapeutic molecules | |
| BR112019014082A2 (pt) | Imunoterapia para hiv sem etapa de pré-imunização | |
| TWI894357B (zh) | 溶瘤病毒與經改造的免疫細胞聯合治療腫瘤 | |
| CN109568350B (zh) | 一种用于治疗肿瘤的柯萨奇病毒 | |
| RU2812046C2 (ru) | Способ продуцирования аренавируса, а также мутантов аренавируса с противоопухолевыми свойствами | |
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof | |
| HK40122461A (zh) | 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体 | |
| CN113583977B (zh) | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 | |
| HK40054624A (en) | Method for producing an antitumoral arenavirus as well as arenavirus mutants | |
| WO2018067165A1 (en) | Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer | |
| HK40054624B (zh) | 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体 | |
| CN115612674B (zh) | 一种溶瘤病毒及其用途 | |
| ES2745103T3 (es) | Partículas inmunosupresivas similares a virus basadas en gammaretrovirus | |
| HK40056184B (zh) | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 | |
| HK40012869A (en) | Oncolytic viruses and therapeutic molecules |